To assess the implications of using adjunctive inhaled antibiotics, particularly nebulized colistin, alongside systemic antibiotics in the treatment of ventilator-associated pneumonia (VAP).
Approach:
Meta-Analysis Review: The article discusses findings from a meta-analysis by Lyu et al. regarding the use of inhaled antibiotics for VAP.
Pharmacokinetic Studies: It reviews pharmacokinetic evidence from studies by Jang et al. and Bihan et al. concerning the systemic absorption of nebulized colistin.
Key Findings:
Nebulized colistin can lead to systemic absorption, potentially causing nephrotoxicity.
Studies show significant differences in nephrotoxicity rates between nebulized and IV colistin.
Pharmacokinetic evidence indicates that nebulized colistin may achieve plasma concentrations similar to IV administration.
Interpretation:
The conclusion by Lyu et al. regarding the use of adjunctive inhaled antibiotics may not fully account for the complexities of systemic absorption, particularly with nebulized colistin.
Limitations:
The findings are based on existing studies, which may not fully elucidate the mechanisms of interindividual variability in drug absorption.
Further pharmacokinetic and prospective clinical studies are needed to clarify the safety and efficacy of combined therapies.
Conclusion:
Nebulized colistin should not be considered solely a local therapy when used concurrently with systemic colistin.
